December 9, 2024 4:40pm

As I wrote this a.m., “momentum mania creates a soon to be a cratering sector; when I see highs, I contemplate bye”

it’s not hard to be right so often, it’s about defining insight and dissecting sentiment

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

Who speaks out while standing in-front, beside and behind investors – RMi

Invest like you're driving on an icy, windy road, not an open highway.

 

RegMed Investors’ (RMi) pre-open: momentum mania creates a soon to be a cratering sector … https://www.regmedinvestors.com/articles/13726

 

Monday: The Dow closed DOWN -240.59 points or -0.54%, the S&P closed DOWN -37.32 points or -0.61% while the Nasdaq closed DOWN -123.08 points or -0.62%

  • The S&P and Nasdaq pulled back from record highs

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • The Fannie Mae Home Purchase Sentiment Index increased 0.4 points last month to 75 points. The index has risen 10.7 points, or more than 16%, in the last year. Forty-five percent of survey respondents say they expect mortgage rates to fall in the next 12 months, while 25% expect them to rise.

Monday’s advance/decline line at the open was positive with 27 incliners, 4 declined and 4 flats; ending with a negative close at the close of 11 incliner, 23 decliners and 2 flats

  • Artificial highs and lows determined by not the sector members but by algorithmic trading

Metrics:  Monday, the IBB was up +0.44%, the XBI was down -0.87% while the VIX was up +1.26 points or +9.87% at 14.03

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”: 

Q4/24 – 2 positive and 4 negative closes

  • November – 1 holiday, 10 negative and 10 positive closes           
  • October: 8 positive and 15 negative sessions

 

Monday’s Closing Down (10 of 23): 

  • Lenz Therapeutics (LENZ -$3.85),
  • CRISPR Therapeutics (CRSP -$2.49 after Friday’s +$2.82),
  • Blueprint Medicine (BPMC -$1.40 after Friday’s +$0.89),
  • Alnylam Pharmaceuticals (ALNY -$0.37 after Friday’s +$4.45),
  • Mesoblast (MESO -$0.26),
  • AxoGen (AXGN -$0.24),
  • uniQure NV (QURE -$0.15 after Friday’s +$0.86),
  • MiMedx (MDXG -$0.11),
  • Intellia Therapeutics (NTLA -$0.10 after Friday’s +$1.07),
  • Voyager Therapeutics (VYGR -$0.08)

Flat (2):

  • Harvard Apparatus RT (OTCQB: HRGN)
  • Homology Medicine (FIXX)

Monday’s Closing Up (11 of 11):

  • Moderna (MRNA +$1.21 after Friday’s +$1.50)
  • Beam Therapeutics (BEAM +$0.81 after Friday’s +$1.39),
  • Verve Therapeutics (VERV +$0.72),
  • Regenxbio (RGNX +$0.59),
  • Ionis Pharmaceuticals (IONS +$0.47 after Friday’s -$1.36),
  • Editas Medicine (EDIT +$0.09),
  • Fate Therapeutics (FATE +$0.07),
  • Solid Biosciences (SLDB +$0.06),
  • BioLife Solutions (BLFS +$0.03 after Friday’s +$1.06
  • Precigen (PGEN +$0.0266),
  • Caribou Biosciences (CRBU +$0.01),

 

The BOTTOM LINE: As I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”

The cell and gene therapy sector stocks kicked off December, the final month of 2024 with

  • A new week, starts with a negative close
  • A Monday positive followed by Thursday and Wednesday, Tuesday’s negative closes and Friday positive close

The next test for indexes and stocks comes in a consumer inflation report, which will set the stage for the Fed's final interest rate decision of the year.

 

Portfolio managers are addressing rotations as year comes to years-end.

  • I keep writing about uncertainty and skepticism … and coming realities.
  • Even with the potential for some market hiccups along the way, the good news is Q4 has historically skewed positively, even as sector earnings kicked the bucket down the road!
  • Never forget end of year tax selling and portfolio rotation due to recommendations are a’comin’!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:    

  • Monday: Moderna (MRNA), Verve Therapeutics (VERV) and Beam Therapeutics (BEAM)

The worst three (3) in the session: 

  • Monday: Lenz Therapeutics (LENZ), CRISPR Therapeutics (CRSP) and Blueprint Medicine (BPMC)

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.